[go: up one dir, main page]

AR121301A2 - Conjugados de anticuerpos basados en eribulina y métodos de uso - Google Patents

Conjugados de anticuerpos basados en eribulina y métodos de uso

Info

Publication number
AR121301A2
AR121301A2 ARP210100338A ARP210100338A AR121301A2 AR 121301 A2 AR121301 A2 AR 121301A2 AR P210100338 A ARP210100338 A AR P210100338A AR P210100338 A ARP210100338 A AR P210100338A AR 121301 A2 AR121301 A2 AR 121301A2
Authority
AR
Argentina
Prior art keywords
eribulin
methods
antibody
drug
drug conjugates
Prior art date
Application number
ARP210100338A
Other languages
English (en)
Inventor
Earl F Albone
Xin Cheng
Keiji Furuuchi
Toshimitsu Uenaka
Daniel W Custar
Jing Li
Utpal Majumder
Original Assignee
Eisai Co Ltd
Morphotek Inc
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd, Morphotek Inc, Eisai Inc filed Critical Eisai Co Ltd
Publication of AR121301A2 publication Critical patent/AR121301A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen toxinas enlazadoras y conjugados de anticuerpo-fármaco que se unen a antígenos diana de oncología humana tal como receptor de folato a y/o proporcionan actividad de fármaco anti-tubulina. Las toxinas enlazadoras y conjugados de anticuerpo-fármaco comprenden un resto de fármaco de eribulina y se pueden internalizar en células que expresan el antígeno diana. La descripción además se refiere a métodos y composiciones para utilizar en el tratamiento de cáncer mediante la administración de los conjugados de anticuerpo-fármaco proporcionados en la presente.
ARP210100338A 2016-03-02 2021-02-10 Conjugados de anticuerpos basados en eribulina y métodos de uso AR121301A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662302562P 2016-03-02 2016-03-02

Publications (1)

Publication Number Publication Date
AR121301A2 true AR121301A2 (es) 2022-05-04

Family

ID=58347964

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP170100524A AR107787A1 (es) 2016-03-02 2017-03-02 Conjugados de anticuerpos basados en eribulina y métodos de uso
ARP210100339A AR121302A2 (es) 2016-03-02 2021-02-10 Conjugados de anticuerpos basados en eribulina y métodos de uso
ARP210100338A AR121301A2 (es) 2016-03-02 2021-02-10 Conjugados de anticuerpos basados en eribulina y métodos de uso

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP170100524A AR107787A1 (es) 2016-03-02 2017-03-02 Conjugados de anticuerpos basados en eribulina y métodos de uso
ARP210100339A AR121302A2 (es) 2016-03-02 2021-02-10 Conjugados de anticuerpos basados en eribulina y métodos de uso

Country Status (35)

Country Link
US (4) US10548986B2 (es)
EP (2) EP3824909A1 (es)
JP (6) JP6599019B2 (es)
KR (4) KR102456433B1 (es)
CN (4) CN114272389B (es)
AR (3) AR107787A1 (es)
AU (2) AU2017225982B2 (es)
BR (1) BR112018067379A2 (es)
CA (1) CA3013791A1 (es)
CL (3) CL2018002456A1 (es)
CO (1) CO2018008667A2 (es)
CY (1) CY1124628T1 (es)
DK (1) DK3423105T3 (es)
ES (1) ES2880402T3 (es)
HR (1) HRP20211125T1 (es)
HU (1) HUE054726T2 (es)
IL (3) IL261428B2 (es)
JO (3) JOP20170053B1 (es)
LT (1) LT3423105T (es)
MA (1) MA45280B1 (es)
MD (1) MD3423105T2 (es)
MX (4) MX2018010562A (es)
MY (2) MY199595A (es)
PE (3) PE20231049A1 (es)
PH (1) PH12018501847A1 (es)
PL (1) PL3423105T3 (es)
PT (1) PT3423105T (es)
RS (1) RS62108B1 (es)
RU (1) RU2754369C2 (es)
SG (2) SG10202007520WA (es)
SI (1) SI3423105T1 (es)
SM (1) SMT202100416T1 (es)
TW (3) TWI871094B (es)
UA (1) UA125024C2 (es)
WO (1) WO2017151979A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1879922A2 (en) * 2005-04-22 2008-01-23 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
CN114409783B (zh) 2015-06-24 2025-09-16 Jcr制药股份有限公司 通过血脑屏障的抗人转铁蛋白受体抗体
HK1247933A1 (en) 2015-06-24 2018-10-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf
WO2018124121A1 (ja) 2016-12-26 2018-07-05 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体
CN110100000B (zh) 2016-12-26 2023-06-20 Jcr制药股份有限公司 含有bdnf的融合蛋白
RS63755B1 (sr) 2017-04-05 2022-12-30 Harvard College Makrociklično jedinjenje i njegova upotreba
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
AU2018364114B2 (en) * 2017-11-08 2024-09-26 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
ES2974243T3 (es) 2017-11-15 2024-06-26 Harvard College Compuestos macrocíclicos y usos de los mismos
EP3801632A1 (en) 2018-06-01 2021-04-14 Eisai R&D Management Co., Ltd. Splicing modulator antibody-drug conjugates and methods of use
BR112020024551A2 (pt) 2018-06-01 2021-03-02 Eisai R&D Management Co., Ltd. métodos para usar moduladores de splicing
JP7458981B2 (ja) 2018-08-06 2024-04-01 第一三共株式会社 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
CN120189526A (zh) 2018-12-13 2025-06-24 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
AU2019409132A1 (en) * 2018-12-21 2021-07-15 Novartis Ag Antibodies to PMEL17 and conjugates thereof
CN110568121A (zh) * 2019-07-11 2019-12-13 山东省药学科学院 一种艾日布林及含艾日布林的制剂中有关物质的检测方法
JP7657213B2 (ja) * 2019-11-07 2025-04-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法
AU2020414996A1 (en) * 2019-12-23 2022-07-14 Eisai R&D Management Co., Ltd. Method for producing eribulin-based antibody-drug conjugate
CA3168654A1 (en) * 2020-01-22 2021-07-29 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
CN113274507B (zh) * 2020-02-20 2025-02-28 亚飞（上海）生物医药科技有限公司 靶向递送和激活的免疫刺激性偶联复合物的制备和用途
CN113509557A (zh) * 2020-04-09 2021-10-19 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
WO2021248005A1 (en) 2020-06-05 2021-12-09 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
WO2022031150A1 (ko) * 2020-08-07 2022-02-10 주식회사 피노바이오 데옥시사이티딘계 항암제 및 실릴 에테르 함유 링커를 포함하는 접합체 및 이의 용도
EP4210751A4 (en) * 2020-09-11 2025-05-21 Alexion Pharmaceuticals, Inc. ANTI-CERULOPLASMIN ANTIBODIES AND THEIR USES
WO2022067224A1 (en) * 2020-09-28 2022-03-31 Navrogen, Inc. Composition and use of alternatively formatted anti-mesothelin antibodies for the treatment of cancer
US20240024502A1 (en) * 2020-10-18 2024-01-25 Ardeagen Corporation Anti-msln binding agents, conjugates thereof and methods of using the same
CN114560940B (zh) * 2020-11-27 2023-07-14 缔码生物科技(武汉)有限公司 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用
IL303332A (en) * 2020-12-04 2023-07-01 Dyne Therapeutics Inc Antibody-oligonucleotide complexes and their uses
WO2021115497A2 (zh) * 2020-12-08 2021-06-17 和铂医药(上海)有限责任公司 蛋白-药物偶联物和定点偶联方法
CN115209922A (zh) * 2021-01-28 2022-10-18 南京桦冠生物技术有限公司 缀合物及其用途
AU2022253902A1 (en) * 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
CN115429893A (zh) * 2021-06-02 2022-12-06 百奥泰生物制药股份有限公司 药物偶联物及其用途
CN117460540A (zh) 2021-07-22 2024-01-26 上海森辉医药有限公司 艾日布林衍生物的药物偶联物
JP2024531258A (ja) * 2021-08-13 2024-08-29 クンシャン シンユンター バイオテック カンパニー，リミティド 微小管阻害剤に基づく抗体薬物複合体
WO2023024949A1 (zh) * 2021-08-24 2023-03-02 昆山新蕴达生物科技有限公司 一种由可断裂连接子偶联的抗体偶联药物
KR20240056587A (ko) * 2021-09-16 2024-04-30 치아타이 티안큉 파마수티컬 그룹 주식회사 항-her3 항체 약물 접합체, 이의 조성물, 및 이의 용도
WO2023055376A1 (en) * 2021-09-30 2023-04-06 Virtuoso Binco, Inc. Multispecific antibodies for targeting cd47 and icam1 and methods of use thereof
CN118103359A (zh) * 2021-10-14 2024-05-28 江苏恒瑞医药股份有限公司 一种艾日布林衍生物的制备方法
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합
US20250049938A1 (en) * 2021-12-01 2025-02-13 Shanghai Institute Of Biological Products Co., Ltd. Antibody-drug conjugate and use thereof
CN118401258A (zh) * 2021-12-09 2024-07-26 昆山新蕴达生物科技有限公司 一种亲和力改善的抗体-药物偶联物、其制备方法及应用
WO2023124963A1 (zh) * 2021-12-27 2023-07-06 昆山新蕴达生物科技有限公司 一种可逆反应减少的抗体-药物偶联物，其制备方法及应用
CN118591394A (zh) * 2022-01-28 2024-09-03 启德医药科技（苏州）有限公司 抗体药物偶联物、药物组合物及用途
CN118591544A (zh) * 2022-01-28 2024-09-03 博瑞生物医药（苏州）股份有限公司 用于制备抗体药物偶联物的连接子、化合物及用途
EP4480499A1 (en) * 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
AU2023231442A1 (en) * 2022-03-11 2024-09-26 Mablink Bioscience Antibody-drug conjugates and their uses
JP2025512327A (ja) * 2022-04-12 2025-04-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンベースの抗体－薬物コンジュゲート及び使用方法
US20250249114A1 (en) * 2022-04-12 2025-08-07 Bio-Thera Solutions, Ltd. Method for treating her2-positive solid tumor
CN120417932A (zh) * 2022-10-14 2025-08-01 启德医药科技（苏州）有限公司 接头-有效载荷化合物、偶联物及其应用
CN117917248A (zh) * 2022-10-20 2024-04-23 英诺湖医药(杭州)有限公司 酶裂解连接子及包含其的配体-艾瑞布林偶联物
EP4619038A2 (en) * 2022-11-14 2025-09-24 Cornell University Anionically functionalized polypeptides, and methods of making same and uses thereof
JP2026502604A (ja) * 2023-01-17 2026-01-23 システィミューン， インク． エリブリン系薬物の複合体
TW202444422A (zh) * 2023-01-19 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 一種含艾日布林衍生物藥物偶聯物的醫藥組成物
WO2024173281A1 (en) * 2023-02-13 2024-08-22 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug conjugate for cancer treatment
WO2024235127A1 (zh) * 2023-05-12 2024-11-21 苏州宜联生物医药有限公司 多弹头抗体偶联药物及其制备方法和用途
WO2024235135A1 (zh) * 2023-05-12 2024-11-21 四川科伦博泰生物医药股份有限公司 大环化合物及其制备方法和用途
CN120957757A (zh) * 2023-05-12 2025-11-14 四川科伦博泰生物医药股份有限公司 大环类药物偶联物及其制备方法和用途
JP2024165695A (ja) 2023-05-18 2024-11-28 セイコーエプソン株式会社 印刷方法、印刷ヘッドユニットおよびロボットシステム
WO2024251240A1 (zh) 2023-06-09 2024-12-12 徕特康(苏州)生物制药有限公司 抗her2互补性双特异抗体-药物偶联物及其制备方法和用途
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof
WO2025081063A2 (en) 2023-10-13 2025-04-17 Eisai R&D Management Co., Ltd. Antibody-drug conjugate metabolites
TW202530697A (zh) 2023-10-13 2025-08-01 日商衛材R&D企管股份有限公司 用於基於艾日布林之抗體－藥物結合物之生物標記及使用方法
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof
CN120131991A (zh) * 2023-12-13 2025-06-13 成都百利多特生物药业有限责任公司 抗人Claudin18.2抗体-喜树碱类药物偶联物及其医药用途
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
WO2025162492A1 (zh) * 2024-01-29 2025-08-07 甘李药业股份有限公司 一种连接子、配体-药物偶联物及其医药用途
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
WO2025228172A1 (zh) * 2024-04-28 2025-11-06 上海拓济医药有限责任公司 艾日布林衍生物及其抗体药物偶联物和医药用途

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5290540A (en) 1991-05-01 1994-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for treating infectious respiratory diseases
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
EP1089712B1 (en) 1998-06-24 2003-05-02 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6019963A (en) 1998-11-20 2000-02-01 D.S.C. Products, Inc. Deodorizing composition containing tea tree and eucalyptus oils
US7109019B2 (en) 1999-01-06 2006-09-19 The Regents Of The University Of California Gene cluster for production of the enediyne antitumor antibiotic C-1027
WO2002087424A2 (en) 2001-05-02 2002-11-07 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
AU2003224644A1 (en) 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
SI2357006T1 (sl) * 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
JP2004119755A (ja) 2002-09-27 2004-04-15 Alps Electric Co Ltd 磁気検出素子及びその製造方法
US20040071540A1 (en) 2002-10-15 2004-04-15 Lucas Philip J. Disposable/recyclable pallet system and method
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
CN1878556A (zh) 2003-09-18 2006-12-13 康宾纳特克斯公司 治疗肿瘤的联合药物
US6997024B2 (en) 2003-10-01 2006-02-14 Truth Hardware Corporation Pull door lock
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
US20050148535A1 (en) 2003-10-30 2005-07-07 Lacasse Eric IAP nucleobase oligomers and oligomeric complexes and uses thereof
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
US7117807B2 (en) 2004-02-17 2006-10-10 University Of Florida Research Foundation, Inc. Dynamically modifiable polymer coatings and devices
WO2006073419A2 (en) 2004-04-01 2006-07-13 Gang Zheng Lipoprotein nanoplatforms
EP1773389A4 (en) 2004-05-07 2008-09-10 Massachusetts Inst Technology METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER RELATING TO THE RECOGNITION OF THE BACH1 PHOSPHORYLE BRCA1 BRCT DOMAIN
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006076100A2 (en) 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
US20060148014A1 (en) 2004-12-09 2006-07-06 Sergei Agoulnik Tubulin isotype screening in cancer therapy using hemiasterlin analogs
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
EP3498289A1 (en) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
GB0515025D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
ES2468240T3 (es) 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
US8129505B2 (en) 2005-09-14 2012-03-06 Ucb Pharma S.A. Comb polymers
EP1968607B1 (en) 2005-12-02 2014-01-15 Nabil Habib Lab Treatment of cancer and other diseases
EP2021502A4 (en) 2006-05-09 2010-08-25 Mas Metabolic Analytical Servi GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY
US20150030534A1 (en) 2013-07-26 2015-01-29 Rutgers, The State University Of New Jersey Antibody cocktails for breast cancer radioimmunotherapy
US20140037539A1 (en) 2012-07-27 2014-02-06 Rutgers, The State University Of New Jersey Antibody cocktails for breast cancer radioimmunotherapy
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ580132A (en) 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
EP1977765A1 (en) 2007-04-03 2008-10-08 Diatos Peptide prodrugs
JP5735277B2 (ja) 2007-10-03 2015-06-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の合成のための中間体および方法
MY188455A (en) * 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
CN101884058B (zh) 2007-10-30 2012-07-25 富士通株式会社 移动终端装置
PL2265283T3 (pl) 2008-03-18 2015-03-31 Seattle Genetics Inc Koniugaty aurystatyny lek łącznik
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
RU2487877C2 (ru) * 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
CN102149690A (zh) 2008-09-12 2011-08-10 参天制药株式会社 含有具有导入了磺酸酯结构的苯基作为取代基的新型1，2，3，4-四氢喹喔啉衍生物的糖皮质激素受体激动剂
CN102300879A (zh) 2008-12-04 2011-12-28 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
SG10201402960SA (en) 2009-03-05 2014-08-28 Abbvie Inc IL-17 Binding Proteins
US20140339088A1 (en) 2009-03-09 2014-11-20 Virginia Tech Intellectual Properties, Inc. Dielectrophoresis methods for determining a property of a plurality of cancer cells
BRPI1012193A2 (pt) 2009-05-01 2019-09-24 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
US8686520B2 (en) * 2009-05-29 2014-04-01 International Business Machines Corporation Spin-torque magnetoresistive structures
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
EP3090758A1 (en) * 2009-08-15 2016-11-09 F. Hoffmann-La Roche AG Anti-angiogenesis therapy for the treatment of previously treated breast cancer
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
WO2011047262A2 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN102803254B (zh) 2010-01-26 2016-09-14 卫材R&D管理有限公司 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
CA2794266C (en) 2010-03-24 2020-09-08 Ohio University Compositions and methods for glucose transport inhibition
PH12012502226A1 (en) 2010-05-14 2013-02-04 Abbvie Inc Il-1 binding proteins
PL2582728T3 (pl) 2010-06-15 2018-01-31 Genmab As Koniugaty ludzkie przeciwciało-lek przeciwko czynnikowi tkankowemu
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ607480A (en) 2010-08-03 2014-10-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US9089570B2 (en) 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US9192677B2 (en) 2010-09-07 2015-11-24 Johannes Kepler Universität Linz Biodegradable, water soluble and pH responsive poly(organo)phosphazenes
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2012075361A2 (en) 2010-12-02 2012-06-07 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
CA2821976A1 (en) 2010-12-21 2012-09-13 Abbvie Inc. Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
US20140024539A1 (en) 2011-02-02 2014-01-23 Translational Genomics Research Institute Biomarkers and methods of use thereof
JP6199746B2 (ja) 2011-02-15 2017-09-20 バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012119077A1 (en) 2011-03-02 2012-09-07 Morphotek Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer
WO2012118978A1 (en) 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
US20150072396A1 (en) 2011-03-04 2015-03-12 Life Technologies Corporation Compounds and Methods for Conjugation of Biomolecules
EP2685988A4 (en) 2011-03-15 2014-08-20 Univ North Carolina Methods of treating breast cancer with anthracycline therapy
ES2731653T3 (es) 2011-03-18 2019-11-18 Eisai R&D Man Co Ltd Métodos y usos para predecir la respuesta a la eribulina
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
EP3470413A3 (en) 2011-05-27 2019-08-07 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
MX371526B (es) 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
WO2012170640A1 (en) 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Methods and compositions for trail-drug combination therapy
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
KR102087854B1 (ko) 2011-06-10 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-중합체-약물 접합체
EP3321281B1 (en) 2011-08-05 2019-11-27 biOasis Technologies Inc P97 fragments with transfer activity
EP2785687B1 (en) 2011-11-30 2019-02-20 Sandoz AG Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
WO2013086634A1 (en) 2011-12-16 2013-06-20 Alphora Research Inc. Process for preparation of 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl) propanol derivatives and intermediates useful thereof
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
EP2794653B1 (en) 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP6300030B2 (ja) 2011-12-29 2018-03-28 サンド アクツィエンゲゼルシャフト ２−（（２ｓ，３ｓ，４ｒ，５ｒ）−５−（（ｓ）−３−アミノ−２−ヒドロキシプロプ−１−イル）−４−メトキシ−３−（フェニルスルホニルメチル）テトラヒドロフラン−２−イル）アセトアルデヒド誘導体およびこれらを調製するためのプロセス
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
WO2013130093A1 (en) * 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2013201584A1 (en) 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
KR20150002706A (ko) 2012-03-29 2015-01-07 알토 바이오사이언스 코포레이션 종양 형성 치료방법
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
BR112014024494A2 (pt) 2012-04-02 2017-08-08 Merrimack Pharmaceuticals Inc dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
AU2013263337A1 (en) 2012-05-15 2014-12-04 Diatech Oncology Tumor cell isolation/purification process and methods for use thereof
EP2850059A4 (en) 2012-05-15 2016-06-29 Concortis Biosystems Corp CONJUGATES OF MEDICATION, METHODS OF CONJUGATION AND USE THEREOF
CA2874854C (en) 2012-06-07 2023-03-14 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
MX2014014831A (es) 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
CN111499684B (zh) 2012-06-19 2024-10-22 Ambrx公司 抗cd70抗体药物结合物
AU2013282391A1 (en) 2012-06-29 2015-01-22 Nanostring Technologies, Inc. Methods of treating breast cancer with gemcitabine therapy
US9220695B2 (en) 2012-06-29 2015-12-29 The Research Foundation For The State University Of New York Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances
ES2939836T3 (es) 2012-07-12 2023-04-27 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
US20140069822A1 (en) 2012-09-10 2014-03-13 Antec Leyden B.V. Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
WO2014047199A1 (en) 2012-09-19 2014-03-27 The Research Foundation For The State University Of New York Novel prodrugs for selective anticancer therapy
EA037368B1 (ru) 2012-10-04 2021-03-19 Аб Сьянс Способ лечения рака поджелудочной железы у пациента, страдающего от связанной с болезнью интенсивной боли, и применение набора, содержащего маситиниб или его фармацевтически приемлемую соль и гемцитаниб, для лечения рака поджелудочной железы
US20150275306A1 (en) 2012-10-10 2015-10-01 Stichting Het Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis Methods and means for predicting resistance to anti-cancer treatment
CN103775148A (zh) 2012-10-22 2014-05-07 张玉良 自冷式热力做功方法
LT2911699T (lt) 2012-10-23 2018-03-26 Synaffix B.V. Modifikuotas antikūnas, antikūnų konjugatas ir jų gavimo būdas
PL2917195T3 (pl) 2012-11-05 2018-04-30 Pfizer Inc. Analogi spliceostatyny
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
SG11201504184PA (en) 2012-12-03 2015-06-29 Calithera Biosciences Inc Treatment of cancer with heterocyclic inhibitors of glutaminase
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
EP2934596A1 (en) 2012-12-21 2015-10-28 Glykos Finland Oy Linker-payload molecule conjugates
US20150182634A1 (en) 2012-12-28 2015-07-02 Cody P. Coyne Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action
WO2014113792A1 (en) 2013-01-19 2014-07-24 New York University Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
US9695153B2 (en) 2013-01-19 2017-07-04 New York University Oligooxopiperazines for p53 reactivation
US20140220112A1 (en) 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
ES2964512T3 (es) 2013-02-01 2024-04-08 Celator Pharmaceuticals Inc Carga remota de fármacos escasamente solubles en agua en liposomas
WO2014124322A1 (en) 2013-02-08 2014-08-14 University Of Louisville Research Foundation, Inc. Nanoparticles for drug delivery
US9333211B2 (en) 2013-02-22 2016-05-10 University Of Houston System Phosphaplatin mediated modulation of pigment epithelial derived factor and uses thereof
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
SG11201507247WA (en) 2013-03-13 2015-10-29 Oncoceutics Inc Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
US20160031887A1 (en) * 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
BR112015023190A2 (pt) 2013-03-14 2017-07-18 Univ Florida regulação de câncer com o uso de compostos e/ou dieta naturais
US20160022829A1 (en) 2013-03-14 2016-01-28 Mersana Therapeutics, Inc. Tubulysin compounds and conjugates thereof
TR201911139T4 (tr) 2013-03-15 2019-08-21 Zymeworks Inc Sitotoksik ve anti-mitotik bileşikler ve bunları kullanmanın yöntemleri.
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
WO2014168721A2 (en) 2013-04-12 2014-10-16 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
HK1222122A1 (zh) 2013-04-22 2017-06-23 Avelas Biosciences, Inc. 选择性药物递送组合物及使用方法
GB2513405A (en) 2013-04-26 2014-10-29 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resins
WO2014177771A1 (en) 2013-05-02 2014-11-06 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
EP2997017B1 (en) 2013-05-15 2017-08-09 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US20140363454A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
US20160299147A1 (en) 2013-06-26 2016-10-13 Afg Technologies S.À.R.L. Screening, diagnosis, prognostication and treatment of ovarian cancer
WO2015000070A1 (en) 2013-07-03 2015-01-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
WO2015017729A1 (en) 2013-07-31 2015-02-05 Virginia Tech Intellectual Properties, Inc. Dielectrophoresis methods for determining a property of a plurality of cancer cells
WO2015017034A1 (en) 2013-08-02 2015-02-05 Gourdie Robert G Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015031541A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Novel sez6 modulators and methods of use
RU2016111131A (ru) 2013-08-28 2017-10-03 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Способы конъюгации сайт-специфических антител и композиции
US20150072021A1 (en) 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
US20150093331A1 (en) 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
US9878049B2 (en) 2013-10-09 2018-01-30 The University Of Akron High drug loading system to co-deliver anticancer drugs and nucleic acids for cancer therapy
EP3054987B1 (en) 2013-10-11 2019-10-09 The United States of America, represented by the Secretary, Department of Health and Human Services Tem8 antibodies and their use
EP3054992B1 (en) 2013-10-11 2019-08-14 Asana BioSciences, LLC Protein-polymer-drug conjugates
DK3054991T3 (da) 2013-10-11 2019-05-06 Mersana Therapeutics Inc Protein-polymer-lægemiddelkonjugater
WO2015061372A1 (en) 2013-10-21 2015-04-30 Hemoshear, Llc In vitro model for a tumor microenvironment
ES2787603T3 (es) 2013-11-04 2020-10-16 Eisai R&D Man Co Ltd Reacciones de macrociclación y productos intermedios útiles en la síntesis de análogos de halicondrina B
KR20160070188A (ko) 2013-11-07 2016-06-17 데시페라 파마슈티칼스, 엘엘씨. 암치료에 유용한 tie2 키나아제의 억제 방법
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
CN110669047A (zh) 2013-11-15 2020-01-10 昂克希尔迪克斯有限公司 用于治疗癌症的化合物、其组合物及应用方法
CA3178867A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
HUE043088T2 (hu) 2013-12-06 2019-08-28 Eisai R&D Man Co Ltd Halikondrin B analógok szintézisében alkalmazható eljárások
US20170020817A1 (en) 2013-12-19 2017-01-26 Luminus Biosciences, Inc. Solid nanoparticle formulation of microtuble inhibitors with reduced ostwald repening for oral administration
EP3092254A4 (en) 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating her2 positive tumors
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
US20160375234A1 (en) 2014-01-10 2016-12-29 Atossa Genetic Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
CN109316605B (zh) 2014-01-20 2023-07-14 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
AU2015212733B2 (en) 2014-02-03 2018-06-07 Eidgenoessische Technische Hochschule Zurich Small molecule drug conjugates
EP3103811A4 (en) * 2014-02-03 2017-11-29 National Cancer Center Anti-tissue factor monoclonal antibody
EP2913064A1 (en) 2014-02-26 2015-09-02 celares GmbH Branched drug-linker conjugates for the coupling to biological targeting molecules
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
CN106488767A (zh) 2014-03-13 2017-03-08 豪夫迈·罗氏有限公司 调节雌激素受体突变体的方法和组合物
US9260478B2 (en) * 2014-04-04 2016-02-16 Shanghui Hu Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
WO2015157471A1 (en) 2014-04-08 2015-10-15 The Methodist Hospital Inos-inhibitory compositions and their use as breast cancer therapeutics
CA2945367A1 (en) 2014-04-14 2015-10-22 Endocyte, Inc. Drug delivery conjugates for treating resistant cancer and for use in combination therapy
WO2015161247A1 (en) * 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Humanized anti-c16orf54 antibodies and methods of use thereof
PT3134125T (pt) * 2014-04-25 2020-01-13 Pf Medicament Conjugado-fármaco-anticorpo e sua utilização para o tratamento de cancro
KR101628872B1 (ko) * 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
US9808528B2 (en) * 2014-06-18 2017-11-07 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
TWI695011B (zh) * 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
EP3069734A1 (en) * 2015-03-17 2016-09-21 Exiris S.r.l. Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
CN116726190A (zh) 2015-06-20 2023-09-12 杭州多禧生物科技有限公司 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物

Also Published As

Publication number Publication date
AU2017225982B2 (en) 2023-10-05
MA45280B1 (fr) 2021-08-31
JP6599019B2 (ja) 2019-10-30
KR20220101204A (ko) 2022-07-19
PE20181953A1 (es) 2018-12-17
UA125024C2 (uk) 2021-12-29
CA3013791A1 (en) 2017-09-08
JP7254861B2 (ja) 2023-04-10
MA45280A (fr) 2019-01-09
KR102445255B1 (ko) 2022-09-22
LT3423105T (lt) 2021-09-10
PE20231050A1 (es) 2023-07-11
HUE054726T2 (hu) 2021-09-28
CO2018008667A2 (es) 2018-08-31
JP2019516664A (ja) 2019-06-20
JP2024174991A (ja) 2024-12-17
RS62108B1 (sr) 2021-08-31
EP3824909A1 (en) 2021-05-26
JP7556086B2 (ja) 2024-09-25
KR20220101203A (ko) 2022-07-19
JP2020128413A (ja) 2020-08-27
SMT202100416T1 (it) 2021-09-14
MX2023003806A (es) 2023-04-12
TWI825834B (zh) 2023-12-11
MD3423105T2 (ro) 2021-10-31
MX2018010562A (es) 2019-02-20
MX2023003809A (es) 2023-04-12
IL261428A (en) 2018-10-31
AR121302A2 (es) 2022-05-04
KR20240007722A (ko) 2024-01-16
EP3423105A1 (en) 2019-01-09
PT3423105T (pt) 2021-07-19
BR112018067379A2 (pt) 2019-01-15
US10548986B2 (en) 2020-02-04
RU2021125492A (ru) 2022-04-05
CN108883198B (zh) 2022-08-09
WO2017151979A1 (en) 2017-09-08
HRP20211125T1 (hr) 2021-10-15
CL2021000049A1 (es) 2021-05-28
TW201800110A (zh) 2018-01-01
JOP20170053B1 (ar) 2021-08-17
IL261428B2 (en) 2025-10-01
IL320940A (en) 2025-07-01
DK3423105T3 (da) 2021-07-26
ES2880402T3 (es) 2021-11-24
CL2018002456A1 (es) 2018-12-21
RU2018134331A (ru) 2020-04-02
CN114191428B (zh) 2024-09-24
CN114191563A (zh) 2022-03-18
KR102702620B1 (ko) 2024-09-05
JP2020019787A (ja) 2020-02-06
SI3423105T1 (sl) 2021-12-31
CL2021000048A1 (es) 2021-05-28
MX2023003808A (es) 2023-04-12
CY1124628T1 (el) 2022-07-22
US20230398228A1 (en) 2023-12-14
MY199595A (en) 2023-11-08
AU2017225982A1 (en) 2018-08-16
NZ744808A (en) 2024-04-26
JOP20210074A1 (ar) 2023-01-30
JP6870051B2 (ja) 2021-05-12
AU2023285804B2 (en) 2025-12-18
AR107787A1 (es) 2018-06-06
JOP20210073A1 (ar) 2023-01-30
TWI871094B (zh) 2025-01-21
SG11201806515RA (en) 2018-09-27
NZ785232A (en) 2025-05-30
TW202408592A (zh) 2024-03-01
RU2754369C2 (ru) 2021-09-01
IL261428B1 (en) 2025-06-01
IL292946B1 (en) 2024-07-01
CN114272389A (zh) 2022-04-05
US20180193478A1 (en) 2018-07-12
JP2021185176A (ja) 2021-12-09
EP3423105B1 (en) 2021-05-05
PH12018501847A1 (en) 2019-05-15
US10322192B2 (en) 2019-06-18
MY189113A (en) 2022-01-26
CN114191428A (zh) 2022-03-18
AU2023285804A1 (en) 2024-01-18
PL3423105T3 (pl) 2021-10-25
PE20231049A1 (es) 2023-07-11
CN108883198A (zh) 2018-11-23
KR20180115330A (ko) 2018-10-22
US20170252458A1 (en) 2017-09-07
KR102456433B1 (ko) 2022-10-19
SG10202007520WA (en) 2020-09-29
IL292946A (en) 2022-07-01
CN114272389B (zh) 2023-04-18
TW202241524A (zh) 2022-11-01
US20200297860A1 (en) 2020-09-24
TWI772288B (zh) 2022-08-01
IL292946B2 (en) 2024-11-01
RU2018134331A3 (es) 2020-08-14
JP2023082096A (ja) 2023-06-13

Similar Documents

Publication Publication Date Title
AR121301A2 (es) Conjugados de anticuerpos basados en eribulina y métodos de uso
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
CL2024001243A1 (es) Conjugados de anticuerpo modulador de empalme - fármaco y métodos de uso.
IL288485A (en) Anti-trop2 antibody-drug conjugates for use in treating cancer
CO2019006455A2 (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
MX366978B (es) Conjugados de anticuerpo - farmaco.
AR102649A1 (es) Anticuerpos anti-cadherina-p y conjugados anticuerpos-fármacos
CO2021006503A2 (es) Conjugados de anticuerpo–fármaco de herboxidieno y métodos de uso
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
UY38265A (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
CL2025001398A1 (es) Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
MX2024012413A (es) Conjugados de anticuerpo-farmaco basados en eribulina y metodos de uso
AR117589A1 (es) Conjugados de anticuerpo modulador de empalme-fármaco y métodos de uso
AR117446A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
AR117686A1 (es) Modulador de empalme de herboxidieno de conjugados de anticuerpo-fármaco y métodos de uso
AR098781A1 (es) Compuestos peptidomiméticos y conjugados anticuerpos-droga de los mismos